Revising domestic development plan of AC-5216, an antianxiety/antidepressant agent

Dainippon Sumitomo Pharma Co., Ltd. (Headquarters: Osaka; President: Kenjiro Miyatake; hereinafter called “DSP”) today announced it has decided to discontinue its already initiated Phase II clinical trial in Japan and revise the domestic development plan of AC-5216, an investigational compound discovered by DSP which is in development for the treatment of depression and anxiety disorders.

DSP has been conducting a Phase II clinical trial in Japan for the treatment of Panic Disorder. Novartis, which has been granted exclusive global development rights outside Japan, Korea, China and Taiwan, has been conducting a Phase II clinical trial in North America for the treatment of Generalized Anxiety Disorder.

After review of the clinical data obtained to date by both DSP and Novartis, DSP has decided to discontinue the Phase II clinical trial in Japan and revise the development plan for this compound including optimal dose.

DSP and Novartis are currently discussing future development plan.